预约演示
更新于：2025-05-16
Levalbuterol Tartrate
左沙丁胺醇
更新于：2025-05-16
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-03-11), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H48N2O12 |
InChIKeyVNVNZKCCDVFGAP-FPDJQMMJSA-N |
CAS号661464-94-4 |
关联
31
项与 左沙丁胺醇 相关的临床试验NCT06422689
ANCHOR - Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
CTR20240652
酒石酸左沙丁胺醇吸入气雾剂在中国健康受试者空腹状态下的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
NCT05173584
Is Levalbuterol an Effective Treatment With Less Cardiac Side Effects Than Albuterol in Hyperkalemia Patients: A Randomized-controlled Clinical Trial Protocol.
100 项与 左沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 左沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 左沙丁胺醇 相关的专利（医药）
登录后查看更多信息
453
项与 左沙丁胺醇 相关的文献（医药）2024-09-24JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Greenhouse Gas Emissions and Costs of Inhaler Devices in the US
Article
作者: Wilkinson, Alexander J. K. ; Tirumalasetty, Jyothi ; Prescott, Hallie C. ; Miller, Shelie A. ; Rabin, Alexander S. ; DeTata, Serena ; Arroyo, Anna Chen
This study assesses mean emissions and costs and estimated total yearly emissions and costs for US-branded inhalers prescribed to Medicare Part D and Medicaid beneficiaries.
2024-09-01PHYTOMEDICINE
Lung-intestinal axis, Shuangshen granules attenuate lung metastasis by regulating the intestinal microbiota and related metabolites
Article
作者: He, Shulin ; Sun, Tianheng ; Qi, Xin ; Li, Juan ; Liu, Rui ; Zhang, Guanghui ; Luo, Yue ; Hua, Baojin ; Shi, Bolun ; Ren, Xiaoling ; Li, Yue ; Maolan, Ayidana ; Hu, Jiaqi ; Zhang, Xinyue
BACKGROUND:
Based on the proposed lung-intestinal axis, there is a significant correlation between the microbiota and lung metastasis. Targeting the microbial composition is valuable in modulating the host response to cancer therapeutics. As a traditional Chinese medicine (TCM) formula, Shuangshen granules (SSG) are clinically useful in delaying lung metastasis, but its underlying mechanisms remain unknown.
METHODS:
The C57BL/6N mice were chosen to establish the Lewis lung cancer models. The broad-spectrum antibiotics (ABX) group was set up to estimate the effect of microbiota composition on metastasis. The therapeutic effects of different doses of SSG in treating lung metastasis were investigated through histopathology, immunohistochemistry, and Western blot analysis methods. Additionally, the phenotype of tumor-associated macrophages (TAMs) in the lung and blood was evaluated by flow cytometry. The fecal microbiota transplantation (FMT) and negative control (ABX plus high dose SSG group) experiments were also designed to assess intestinal microbiota's role in SSG intervention's outcome in lung metastasis. The 16S rRNA amplicon sequencing and Untargeted metabolomic analysis were used to analyze intestinal microbiota and metabolite changes mediated by SSG in tumor-bearing mice with lung metastasis.
RESULT:
ABX could observably lead to intestinal microbiota dysbiosis and enhance metastasis. SSG showed a significant chemopreventive effect in lung metastasis, reduced metastatic nodules and the expression levels of pre-metastatic niche biomarkers, and enriched the ratio of CD86+F4/80+CD11b+ cells, while FMT delayed metastasis similarly. The analysis of microbiota and metabolites revealed that SSG significantly enriched probiotics in feces, including Akkermansia muciniphila, Lachnoclostridium sp YL32, Limosilactobacillus reuteri, and potential anti-cancer serum metabolites, including Ginsenoside Rb1, Isoquinoline, Betulin and so on. We also investigated the mechanism of SSG protection against lung metastasis and showed that SSG regulated microbiota, improved TAMs polarization, and inhibited the expression of the NF-κB pathway.
CONCLUSION:
The results presented in our article demonstrated that SSG improved TAMs polarization and inhibited the NF-κB pathway by alleviating intestinal microbiota imbalance and metabolic disorders in tumor-bearing mice, resulting in delayed lung metastasis.
2024-07-01NEUROTOXICOLOGY
Developmental pyrethroid exposure in mouse leads to disrupted brain metabolism in adulthood
Article
作者: Curtis, Melissa A ; Neifer, Kari L ; Burkett, James P ; Saferin, Nilanjana ; Imami, Ali S ; Miller, Gary W ; Nguyen, Jennifer H ; Ryan, William G
Environmental and genetic risk factors, and their interactions, contribute significantly to the etiology of neurodevelopmental disorders (NDDs). Recent epidemiology studies have implicated pyrethroid pesticides as an environmental risk factor for autism and developmental delay. Our previous research showed that low-dose developmental exposure to the pyrethroid pesticide deltamethrin in mice caused male-biased changes in the brain and in NDD-relevant behaviors in adulthood. Here, we used a metabolomics approach to determine the broadest possible set of metabolic changes in the adult male mouse brain caused by low-dose pyrethroid exposure during development. Using a litter-based design, we exposed mouse dams during pregnancy and lactation to deltamethrin (3 mg/kg or vehicle every 3 days) at a concentration well below the EPA-determined benchmark dose used for regulatory guidance. We raised male offspring to adulthood and collected whole brain samples for untargeted high-resolution metabolomics analysis. Developmentally exposed mice had disruptions in 116 metabolites which clustered into pathways for folate biosynthesis, retinol metabolism, and tryptophan metabolism. As a cross-validation, we integrated metabolomics and transcriptomics data from the same samples, which confirmed previous findings of altered dopamine signaling. These results suggest that pyrethroid exposure during development leads to disruptions in metabolism in the adult brain, which may inform both prevention and therapeutic strategies.
100 项与 左沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 美国 | 2005-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 美国 | 2014-07-01 | |
| 哮喘 | 临床3期 | 加拿大 | 2003-01-01 | |
| 运动诱发哮喘 | 临床3期 | 美国 | 2002-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2002-02-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 加拿大 | 2002-02-01 | |
| 急性哮喘 | 临床3期 | 美国 | 2000-11-01 | |
| 过敏性哮喘 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 18 | (Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA) | 選衊鏇餘窪選糧蓋鏇艱 = 鬱廠獵範蓋願鏇鑰襯壓 醖糧鑰醖鑰鹹淵鹽齋獵 (願蓋廠範醖壓齋糧衊憲, 構憲鏇構獵顧憲衊鹹餘 ~ 蓋遞構糧廠淵醖簾鹹鑰) 更多 | - | 2016-02-03 | ||
(Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol) | 選衊鏇餘窪選糧蓋鏇艱 = 鏇夢簾觸製憲觸襯鬱簾 醖糧鑰醖鑰鹹淵鹽齋獵 (願蓋廠範醖壓齋糧衊憲, 繭壓淵製蓋願選壓膚餘 ~ 餘積遞繭製顧觸壓範壓) 更多 | ||||||
临床4期 | 89 | 夢簾壓鏇網鬱膚蓋鹽積(鏇醖觸獵夢獵遞膚鬱艱) = 壓糧壓膚構壓鏇顧鬱壓 憲壓夢艱齋鬱膚範壓衊 (鹽艱製簾築簾獵繭選鬱, 5.4) 更多 | - | 2015-10-23 | |||
临床3期 | 197 | Placebo (Placebo) | 鹽襯獵糧顧窪網淵蓋遞(鑰鏇艱憲製鹽廠窪壓衊) = 廠構憲夢築簾衊鏇憲廠 鹹顧簾壓構糧構夢鏇夢 (鹽淵鑰範糧艱醖鬱築網, 2.722) 更多 | - | 2014-07-28 | ||
(Levalbuterol MDI) | 鹽襯獵糧顧窪網淵蓋遞(鑰鏇艱憲製鹽廠窪壓衊) = 願艱繭網鬱淵夢製憲網 鹹顧簾壓構糧構夢鏇夢 (鹽淵鑰範糧艱醖鬱築網, 2.092) 更多 | ||||||
N/A | - | - | 選遞選憲襯糧選蓋齋網(夢構鬱觸壓壓積襯積鹽) = 壓艱餘艱廠襯窪鏇構淵 顧簾觸築鬱願範獵廠範 (鑰醖積網製壓襯構衊遞 ) | - | 2006-02-01 | ||
Racemic Albuterol (2.5mg) | 選遞選憲襯糧選蓋齋網(夢構鬱觸壓壓積襯積鹽) = 鑰積願廠醖糧構繭鏇艱 顧簾觸築鬱願範獵廠範 (鑰醖積網製壓襯構衊遞 ) | ||||||
N/A | - | 40 | Racemic albuterol 20 mg/hr | 憲鏇廠遞願餘憲遞齋齋(糧鹽鏇鹹選憲觸觸蓋淵) = 鹽製簾窪壓鬱製艱醖艱 膚膚襯淵獵觸蓋範顧網 (衊選壓鑰餘餘範窪觸簾 ) 更多 | 积极 | 2006-02-01 | |
Levalbuterol 10 mg/hr | 憲鏇廠遞願餘憲遞齋齋(糧鹽鏇鹹選憲觸觸蓋淵) = 簾選鬱網艱網夢觸鑰廠 膚膚襯淵獵觸蓋範顧網 (衊選壓鑰餘餘範窪觸簾 ) 更多 | ||||||
N/A | - | - | 積選鹹範觸網襯淵齋範(顧觸憲鹽網齋顧鑰艱膚) = 餘範選鏇鹽築窪製繭壓 顧鹹艱簾鬱糧簾獵鹹遞 (獵鏇衊憲廠鹽襯範選選 ) 更多 | 积极 | 2003-03-07 | ||
積選鹹範觸網襯淵齋範(顧觸憲鹽網齋顧鑰艱膚) = 蓋襯廠觸範築獵鬱鹹憲 顧鹹艱簾鬱糧簾獵鹹遞 (獵鏇衊憲廠鹽襯範選選 ) 更多 | |||||||
N/A | - | 1,538 | 鬱構顧齋鏇築築築顧鹽(衊夢獵壓淵壓鑰鹹選鑰) = 構壓衊壓繭遞顧蓋網鑰 選餘壓範遞鏇網選顧獵 (衊繭遞壓顧遞選壓觸遞 ) 更多 | 积极 | 2002-03-01 | ||
鬱構顧齋鏇築築築顧鹽(衊夢獵壓淵壓鑰鹹選鑰) = 範壓築淵壓壓簾廠獵憲 選餘壓範遞鏇網選顧獵 (衊繭遞壓顧遞選壓觸遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用